

JUL 12
JUL 22 2003

PATENT

Customer No. 22,852

Attorney Docket No. 08702.0086-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Manas Kumar MAJUMDAR et al.) Group Art Unit: 1646
Application No.: 10/078,808) Examiner: J.L. Andres
Filed: February 19, 2002)
For: CHONDROGENIC POTENTIAL OF)
HUMAN BONE MARROW-DERIVED)
CD105⁺ CELLS BY BMP)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RECEIVED

JUL 7 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT


In a Restriction Requirement dated June 4, 2003, the Examiner required restriction under 35 U.S.C. § 121 between Group I (Claims 1, 5, 9-10, 13-20 and 28-31) drawn to compositions of BMPs and cells, and Group II (Claims 2-4, 6-8, 11-12 and 21-27) drawn to methods of treatment using BMP's and cells. Applicants elect to prosecute Group II, Claims 2-4, 6-8, 11-12 and 21-27, drawn to methods of treatment using BMP's and cells.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:


Leslie A. McDonell
Reg. No. 34,872

Dated: July 3, 2003

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com